Aprea Therapeutics, Inc.
APREAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Aug 13, 2026 |
| Wedbush | maintain | Outperform | May 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2026 |
| Wedbush | maintain | Outperform | Mar 31, 2026 |
| Wedbush | maintain | Outperform | Feb 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 29, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| Wedbush | maintain | Outperform | Aug 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| Wedbush | maintain | Outperform | Mar 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2023 |
| Maxim Group | maintain | Buy | Mar 10, 2023 |
| Wedbush | maintain | Outperform | Jul 8, 2022 |
| HC Wainwright & Co. | maintain | Neutral | Mar 16, 2022 |
Earnings History
Next report: Mar 15, 2027 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.09 | $-0.07 | — | $307.5K |
| Aug 12, 2026 | $-0.07 | $-0.18 | — | $253.0K |
| May 13, 2026 | $-0.22 | $-0.23 | $140.5K | — |
| Mar 16, 2026 | $-0.32 | $-0.38 | $3.3K | $3.3K |
| Nov 12, 2025 | $-0.47 | $-0.11 | $1.8K | — |
| Aug 12, 2025 | $-0.53 | $-0.77 | $118.1K | — |
| May 14, 2025 | $-0.66 | $-0.65 | $162.5K | — |
| Mar 25, 2025 | $-0.49 | $-0.69 | $205.8K | $225.0K |
News
DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D.
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 clinical trial expanded to nine sites, with immunohistochemistry (IHC) testing for Cyclin E expression now in place to support biomarker assessment and future patient selection strategies $37.8 million in cash and cash equivalents as of September 30, 2026; cash runway expected into Q1 2028 DOYLESTOW…
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it will host a virtual panel discussion, "The State of WEE1 Inhibition in Precision Oncology," on Tuesday, October 20, 2026, at 11 am ET.
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentatio…
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances